

Plans for Rocklatan to launch in Europe

After the launch of Rocklatan in the USA, Aerie Pharmaceuticals will be discussing plans for a European approval at the Ophthalmic Drugs conference in November

LONDON, ENGLAND, UNITED KINGDOM, June 25, 2019

/EINPresswire.com/ -- Last month Aerie Pharmaceuticals announced that they had received approval from the FDA for Rocklatan, the once a day eye drop designed specifically for patients with open-angle glaucoma, reducing IOP elevation*, making them the first company to get to market with this innovative product. The drug has been released in the US with plans being made for a European approval.

[At SMi's 3rd annual Ophthalmic Drugs conference](#), taking place in London on 18th -20th November 2019, Mitchell de Long, Vice President of Chemistry from Aerie Pharmaceuticals will discuss the launch of Rocklatan in the USA, with a focus on drug development and more specifically the ROCK inhibitor class of drugs. He will share his experiences on gaining the first FDA approval for a PG combination product and discuss the future landscape for Glaucoma treatment.

Following Mitchell's presentation on Tuesday 19th November, Naj Sharif, Vice President of Global Ophthalmology at Santen Inc USA, will continue in a similar vein where he will focus on novel treatment modalities for managing ocular hypertension and Glaucoma.

Mitchell and Naj will also be chairing [the Conference](#) on both Day One and Day Two.

The brochure with the full programme and speaker line-up is available online at www.ophthalmicdrugs.com

For those interested in attending, there is a £300 early bird discount on booking expiring on 28th June. Places can be reserved at www.ophthalmicdrugs.com

*Glaucoma.org/news

[Ophthalmic Drugs](#)

Conference: 19th-20th November 2019

Focus Day: 18th November 2019



SMi Presents the 3rd Annual...
OPHTHALMIC DRUGS

**COPTHORNE TARA
HOTEL,
LONDON, UK**

**18 - 20
NOV
2019**

www.ophthalmicdrugs.com

Ophthalmic Drugs 2019

Copthorne Tara Hotel, London, UK
#OphthalmicDrugs

Ophthalmic Drugs 2019 is proudly sponsored by Experimentica and ProMed Pharma.

For exclusive tailored sponsorship/table-top opportunities contact: Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: nhoward@smi-online.co.uk

---end---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Neill Howard
SMi Group
+442078276164
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.